Tianjin Chase Sun Pharmaceutical Co., Ltd. provided earnings guidance for the nine months ended September 2013. The company predicted net profit attributable to shareholders of CNY 237.5306 million to CNY 255.1255 million in January-September period, rising 35% to 45% year on year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.27 CNY | -0.30% | -4.66% | -22.88% |
03-01 | Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue | MT |
02-29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.88% | 1.35B | |
+32.48% | 5.8B | |
-26.22% | 3.92B | |
+4.73% | 3.28B | |
-20.86% | 2.77B | |
-11.88% | 2.26B | |
+46.64% | 1.95B | |
-16.71% | 1.52B | |
+44.65% | 1.49B | |
-9.60% | 1.49B |
- Stock Market
- Equities
- 300026 Stock
- News Tianjin Chase Sun Pharmaceutical Co.,Ltd
- Tianjin Chase Sun Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Nine Months Ended September 2013